Does Blue Cross Blue Shield Cover Prolia?
The verdict
Covered on most plans
BCBS plans cover Prolia, but there is no single national Blue Cross policy — there are 30-plus independent licensees, each with its own medical policy and PBM relationship. Prolia is most often covered under the medical benefit as a clinician-administered injection billed under HCPCS J0897 every 6 months, with prior authorization required across most licensees. Several BCBS entities have moved to the Jubbonti biosimilar as the preferred denosumab product as of 2025. Always confirm coverage under your specific state BCBS medical policy.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Blue Cross Blue Shield using your member ID.
Key facts
BCBS is 30-plus independent licensees — there is no single national Prolia policy. Independence Blue Cross and Blue Shield of California now prefer the Jubbonti biosimilar over branded Prolia as of September 2025.
Independence Blue Cross formulary announcement Sept. 1, 2025; Blue Shield of California drug policy
Prolia is most often a Medicare Part B buy-and-bill drug billed under HCPCS J0897 — not a Part D pharmacy pickup. The $2,100 Part D OOP cap does not apply to the Part B pathway.
CMS Local Coverage Determination L33394; Medicare.gov
BCBS North Carolina issued new Part B prior authorization criteria for denosumab (Prolia/Jubbonti), HCPCS J0897, effective August 1, 2025 — illustrating how individual BCBS licensees set their own policies.
BCBS North Carolina medical policy update, Aug. 1, 2025
Medicare vs. commercial coverage
Whether Blue Cross Blue Shield covers Prolia depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part B (medical benefit): Prolia is covered as a clinician-administered subcutaneous injection every 6 months, billed under HCPCS J0897 incident to a physician service per LCD L33394. On Original Medicare plus a BCBS Medigap plan, the member pays 20% Part B coinsurance after the Part B deductible; a Medigap supplement typically covers that 20%. Several BCBS licensees have issued specific Part B PA criteria for denosumab in 2025: BCBS North Carolina issued PA criteria for J0897 effective August 1, 2025; Independence Blue Cross designated Jubbonti (denosumab-bddz) as the preferred denosumab product effective September 1, 2025; Blue Shield of California requires step therapy through Jubbonti before branded Prolia is approved. Existing Prolia authorizations transitioned to Jubbonti on plans where the biosimilar was adopted. Verify your specific BCBS licensee's Medicare Part B medical policy for current PA requirements.
Commercial / Employer
Group & marketplace plans
Commercial/Employer: covered under the medical benefit with prior authorization across most BCBS licensees. Documentation of osteoporosis with high fracture risk is required (T-score at or below -2.5, prior fragility fracture, or high FRAX score). PA approval duration is typically 12 months. Biosimilar preference (Jubbonti) is emerging and varies by licensee. ACA/Individual: covered with PA on BCBS Marketplace plans where offered; licensee-specific terms apply. Medicaid: BCBS-managed Medicaid plans cover Prolia for osteoporosis with high fracture risk per state preferred drug list at nominal cost-share with PA. Not covered outside FDA-approved osteoporosis and bone-loss indications on any BCBS line of business. Because BCBS is a federation, tier placement, cost-share, and biosimilar requirements differ by state plan — verify on your state BCBS medical policy or drug-lookup tool.
The 3 boxes you must tick to get approved
Commercial plans that will consider Prolia require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 3 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Prolia actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
~$1,786–$2,507 per 60 mg dose without insurance (estimates: Medicare.org ~$1,786; GoodRx ~$2,507). Actual cash price varies by site of care.
List price with no coverage — before any manufacturer savings card.
With coverage
Original Medicare Part B with BCBS Medigap: 20% coinsurance after the Part B deductible; Medigap typically covers the 20%, reducing out-of-pocket to $0. Medicare Advantage (BCBS-affiliated): observed MA plan copays range $0–$500 per injection depending on plan design — verify on your specific BCBS MA plan. Commercial/Employer: medical-benefit coinsurance per plan; varies by licensee cost-share structure. Medicaid: nominal cost-share per state PDL. Because BCBS is 30-plus licensees, do not rely on a generic national cost figure — verify on your state BCBS plan documents.
Typical monthly copay once prior authorization is approved.
Bridge program
Amgen offers copay support for Prolia to commercially insured patients. This program is NOT available to Medicare or Medicaid beneficiaries under federal anti-kickback rules.
Reduced copay through the assistance program, where eligible.
All figures are estimates. The Part D $2,100 out-of-pocket cap does NOT apply to the Part B medical pathway — Prolia and Jubbonti are Part B drugs for most BCBS members on Medicare. Verify your cost-share with your specific state BCBS plan.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Find your specific BCBS licensee and look up its Prolia medical policy
BCBS is a federation of 30-plus independent companies. Go to your state BCBS website (for example, bcbsil.com, bcbsnc.com, independence.com, blueshieldca.com, or carefirst.com) and search for 'denosumab' or 'Prolia' in the medical policies section. Do not rely on a generic national Blue Cross page — each licensee has its own PA criteria and biosimilar rules.
- 2
Ask your clinician whether Jubbonti or Prolia is authorized on your plan
As of 2025, several BCBS licensees (Independence Blue Cross, Blue Shield of California, and others) prefer the Jubbonti biosimilar (denosumab-bddz) over branded Prolia. Your prescriber can confirm which product your BCBS plan currently covers and whether a step-therapy requirement applies. If your existing Prolia authorization was active when your licensee switched to Jubbonti, it likely carried over automatically — confirm this with your prescribing clinician.
- 3
Verify Part B vs. Part D benefit routing and your cost-share
For Medicare members on a BCBS Medigap supplement, Prolia is a Part B medical-benefit drug — not a Part D pharmacy drug. Confirm this under your Part B benefits section. For BCBS Medicare Advantage members, check your plan's drug and medical benefit cost-sharing documents for the denosumab/J0897 cost-share. Call the member-services number on your ID card for an estimate specific to your plan.
Options if Blue Cross Blue Shield won't cover Prolia
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Jubbonti (denosumab-bddz)
The FDA-approved interchangeable biosimilar for Prolia, containing the same denosumab molecule at the same 60 mg dose and q6-month schedule. Multiple BCBS licensees now prefer or require Jubbonti before branded Prolia. Existing Prolia authorizations typically transition automatically.
Fosamax (alendronate) — generic bisphosphonate
Generic alendronate is an oral osteoporosis treatment covered at Tier 1 on most formularies. Often considered first-line before specialty injectables; some BCBS plans may consider bisphosphonate treatment history when evaluating a Prolia or Jubbonti PA request.
Reclast (zoledronic acid)
Annual IV bisphosphonate infusion administered in a clinic, billed under the medical benefit. Covered at a lower cost than Prolia on most plans. An option for patients who cannot tolerate oral bisphosphonates.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
No. Blue Cross Blue Shield is a federation of 30-plus independent licensees, not a single national insurer. Each licensee writes its own medical policy for Prolia and denosumab. Some now require Jubbonti biosimilar first (Blue Shield of California, Independence Blue Cross); others are still updating their 2025 policies. Always pull your specific state BCBS medical policy for Prolia or denosumab rather than relying on any national summary.
As of 2025, Independence Blue Cross made Jubbonti the preferred denosumab product effective September 1, 2025. Blue Shield of California requires step therapy through Jubbonti before branded Prolia. BCBS North Carolina issued new Part B prior authorization criteria for denosumab (HCPCS J0897) effective August 1, 2025. The broader trend across BCBS licensees is toward Jubbonti preference — verify with your specific plan for current requirements.
For most BCBS members — especially those on Medicare — Prolia is a medical-benefit drug administered as an in-office injection every 6 months and billed under HCPCS J0897 per LCD L33394. It is not picked up at a pharmacy under Part D. This matters for cost-sharing: the $2,100 Part D out-of-pocket cap does not apply to the Part B medical pathway. Medigap covers the 20% Part B coinsurance for many BCBS supplement members.
No. The $2,100 Part D out-of-pocket cap (2026) applies to Part D pharmacy drugs. Prolia and Jubbonti are most often administered and billed under Part B as a medical-benefit drug for Medicare members. Part B cost-sharing follows your Part B coinsurance structure — 20% of the Medicare-approved amount after the Part B deductible — not the Part D cap. If you have a BCBS Medigap plan, that supplement typically covers the 20%.
PA is required across most BCBS licensees. Typical documentation: T-score at or below -2.5, prior fragility fracture, or a high FRAX score indicating elevated 10-year fracture probability. Original Medicare does not require PA but requires clinical documentation. BCBS Medicare Advantage plans may require both PA and step therapy through the Jubbonti biosimilar. PA approval is typically 12 months; verify your licensee's specific criteria.
Related Articles
Does BCBS Michigan Cover Contrave? 2026 MI Guide | Curex
BCBS Michigan upheld weight-loss exclusions (DIFS 2025). Contrave is plan-dependent. MI Medicaid favors weight-loss GLP-1s; Contrave varies by PDL.
Read moreDoes BCBS of Illinois Cover Jardiance? 2026
BCBS of Illinois (HCSC) covers Jardiance across commercial, ACA, Medicare, and Medicaid. Metformin-first step is common. 2026 MFP $197 for Medicare.
Read moreDoes BCBS Alabama Cover Wegovy? 2026 Guide | Curex
BCBS Alabama Wegovy coverage is employer-dependent and unpublished. Alabama Medicaid excludes obesity GLP-1s. How to verify your specific plan.
Read moreDoes Blue Cross Blue Shield of Minnesota Cover Mounjaro? 2026 | Curex
BCBS of Minnesota covers Mounjaro for type 2 diabetes with PA — not weight loss. MN Medicaid covers weight-loss GLP-1s for Zepbound, not Mounjaro.
Read moreDoes Blue Cross Blue Shield Cover Ambien? 2026 | Curex
Blue Cross Blue Shield covers generic zolpidem (Tier 1–2); brand Ambien is non-preferred. Quantity limits apply. Verify your specific BCBS plan for 2026.
Read moreDoes BCBS of Texas Cover Ozempic? 2026 Guide | Curex
BCBS Texas (HCSC) covers Ozempic for T2D with PA — not weight loss. HCSC shares PA with BCBS IL. TX Medicaid uses separate Star MCOs. Verify on BCBS TX.
Read moreThis content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Blue Cross Blue Shield before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation.